Business Context and Reporting Period
Envue Medical, Inc. (Nasdaq: FEED) filed a Current Report on Form 8-K dated January 30, 2026. The filing reports the entry into a material definitive agreement and a material modification to the rights of security holders regarding the Company's Series H Convertible Preferred Stock.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only specific financial figure disclosed is the exercise of an $2,500,000 Additional Investment Right by holders of the Series H Convertible Preferred Stock.
Material Changes
- Amendment to Certificate of Designations: On January 30, 2026, the Company entered into an Amendment Agreement with Required Holders of the Series H Convertible Preferred Stock.
- Removal of Floor Price: The primary change is the removal of the "Floor Price" provision from the Certificate of Designations for the Series H stock.
- Consideration: This amendment was executed in consideration of the holders exercising $2,500,000 of their Additional Investment Right, originally established in the July 18, 2025, Securities Purchase Agreement.
- Regulatory Filing: The Company filed the Certificate of Amendment with the Secretary of State of Delaware, which became effective immediately upon filing.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or a discussion of general business risks. The document focuses exclusively on the legal modification of the Series H Convertible Preferred Stock terms. No unusual items or contingencies are disclosed beyond the specific transaction described.
Investor Verification Checklist
- Verify the full text of the Amendment Agreement (Exhibit 10.1) to understand any other terms modified alongside the Floor Price removal.
- Review the Certificate of Amendment (Exhibit 3.1) to confirm the exact legal language regarding the Floor Price deletion.
- Confirm the impact of the $2,500,000 investment on the Company's current cash position and capitalization table.
- Assess how the removal of the Floor Price affects the conversion mechanics and potential dilution for common shareholders.